Test Name:
ABL1 Tyrosine Kinase Domain Mutation Analysis
CPT Code:
81170/81206/81207
Turn Around Time:
3 – 7 days
Clinical Application:
Analyzes the patient-specific ABL1 tyrosine kinase domain sequence of the BCR::ABL1 fusion transcript to determine the presence of imatinib resistance mutations in ABL1 TKD
Methodology:
Sanger sequencing. LoD: 20%.
Specimen Requirements:
RNA-based assays
Peripheral Blood: Minimum 2 mL in EDTA (purple top) preferred or 2 mL in sodium heparin (green top)
Bone Marrow: Minimum 2 mL in EDTA (purple top) preferred or 2 mL in sodium heparin (green top)
Storage and Transportation:
Please store and ship specimens at ambient temperatures.
Ship RNA-based assays within 24 hours for optimal results.
Please refer to our full specimen requirements at Hematologics/Specimen Requirements for additional information and for directions on the storage and shipping of extracted DNA or RNA.